Datapoint: Jardiance Joins Farxiga in CKD Market Basket

The FDA on Sept. 22 approved Eli Lilly and Boehringer Ingelheim’s Jardiance “to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with chronic kidney disease (CKD) at risk of progression.” The approval means Jardiance will go up against its rival SGLT2 inhibitor, AstraZeneca’s Farxiga, which gained approval for CKD in 2021. For the treatment of CKD, Farxiga holds covered or better status for 95% of all insured lives under the pharmacy benefit. 47% of lives have preferred access to Farxiga without utilization management restrictions.

SOURCE: MMIT Analytics, as of 9/27/23

0

0

0 Comments

0

0

• Datapoint